References
- Nadeem K et al. Clinical decisions following implementation of
asparaginase activity monitoring in pediatric patients with acute
lymphoblastic leukemia: Experience from a single-center study.
Pediatric Blood and Cancer 2019;e28044:1-7.
- Tong WH, Pieters R, Kaspers GJL, et al. A prospective study on drug
monitoring of PEGasparaginase and Erwinia asparaginase and
asparaginase antibodies in pediatric acute lymphoblastic leukemia.
Blood. 2014;123:2026-2034.Wacker P et al. Allergic Reactions to E.Coli
L-Asparaginase Do Not Affect Outcome in Childhood B-precursor Acute
Lymphoblastic Leukemia. A Children’s Oncology Group Study. J Pediatr
Hematol Oncol 2007;29(9):627-632.
- Marini et al. A single-center multidisciplinary approach to managing
the global Erwinia asparaginase shortage. Leukemia & Lymphoma
2019;60(12):2854-2868.
- U.S Department of Health and Human Services. National Cancer Institute
Division of Cancer Treatment and Diagnosis. Common Terminology
Criteria for Adverse Events (CTCAE) Version 5.0 Published: November
27, 2017. Available at:
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50
- Salzer W et al. (2017). Asparaginase activity levels and monitoring in
patients with acute lymphoblastic leukemia. Leukemia and Lymphoma,
1-10.
- Van der Sluis IM et al. Consensus expert recommendations for
identification and management of asparaginase hypersensitivity and
silent inactivation. Haematologica 2016;101(3):279-285.
- Marini BL, Perissinotti AJ, Bixby DL, et al. Catalyzing improvements
in ALL therapy with asparaginase. Blood Rev. 2017;31:328–338.
- Burke MJ, Rheingold SR. Differentiating hypersensitivity versus
infusion-related reactions in pediatric patients receiving intravenous
asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma.
2017;58:540–551.
- Network NCC. Clinical Practice Guidelines in Oncology - Acute
Lymphoblastic Leukemia. Version 1.2018. 2018.
- Gupta S, Rau R et al. A Phase 3 Trial Investigating Blinatumomab
(IND# 117467, NSC# 765986) in Combination with Chemotherapy in
Patients with Newly Diagnosed Standard Risk or Down syndrome
B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with
Localized B-Lymphoblastic Lymphoma (B-LLy). Children’s Oncology Group.
- O’Brien M, McNeer J et al. A Phase 3 Randomized Trial of Inotuzumab
Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk
B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed
Phenotype Acute Leukemia, and Disseminated B-LLy
- Young D, Bowen C, Arwood N, et al. Universal Pretreatment for
Asparaginase-Based Therapy Should be Standard of Care. ASPHO 2018.
2018 (Abstract 2024). [cited 2018 Oct 17]. Available from:
https://aspho.planion.com/Web.User/AbstractDet?ACCOUNT1⁄4
ASPHO&ABSID1⁄413563&CONF1⁄4AM18&ssoOverride1⁄4O- FF&CKEY.
- Pike M, Kulkarni K, MacDonald T. Supratherapeutic levels of
asparaginase: therapeutic drug monitoring experience from the
Maritimes, Canada. Leukemia and Lymphoma 2019;60(9):2312-2315.